Effective September 27, 2024, TEGSEDIĀ® (inotersen) is no longer available to patients in the US.
At the request of Akcea Therapeutics, the US Food and Drug Administration (FDA) updated the marketing status to “discontinued” and the company ceased distribution of TEGSEDI. These activities were not due to any safety reasons associated with the use of TEGSEDI.
As a result of product discontinuation in the US, the TEGSEDI REMS (Risk Evaluation and Mitigation Strategy) is no longer in effect.
If you have questions, please contact Akcea at 1-833-829-9063.